Eli Lilly (Indianapolis, IN, US) and (Bagsvaerd, Denmark) have announced that the supply of their GLP-1 weight loss drugs has improved, with the FDA shortages database now reporting increased availability of some doses of Zepbound, Mounjaro, Wegovy, and the diabetes drug Trulicity. The situation is improving for GLP-1 receptor agonist supply, particularly for Lilly’s tirzepatide products, Zepbound and Mounjaro. However, it is too early to tell if the supply and demand dynamics have become more balanced in the long term.
Fluctuating demand may still result in periodic supply tightness for certain presentations and dose levels as Lilly and Novo continue to expand drug production. The gold standard of business intelligence. Most versions of Mounjaro and Zepbound injections are now available, Lilly reported to the FDA on 2 August, after a long period of limited availability.
On the same date, Novo declared the availability of two versions of Wegovy (semaglutide) (0.5mg/0.5mL and 1mg/0.
5mL). All versions of Ozempic (semaglutide) and most versions of Wegovy are now available in the US market. Lilly’s Trulicity (dulaglutide), approved for diabetes, also became classed as available for 1.
5mg/0.5mL doses, although half the dosage concentrations in the US are still classed as limited availability. Three starter doses of Novo’s Wegovy (semaglutide) are still listed as having limited availability, with the estimated duration of shortage “to be determined”.
In other geographies,.